Hypothesis

Increasing the surface density of functional BKCa calcium‑activated potassium exosomes enhances recipient cell calcium homeostasis, which in turn promotes ESCRT‑dependent loading of therapeutic RNAs and proteins, thereby improving the efficacy of exosome‑based drug delivery.

Mechanistic Rationale

Exosomes naturally incorporate BKCa channels that stabilize their membrane during intercellular transfer [3]. BKCa activity modulates local membrane potential and calcium flux, influencing the activity of calcium‑sensitive sorting machinery such as ALIX and TSG101. We propose that elevating BKCa copy number raises intracellular calcium microdomains in target cells, activating calmodulin‑dependent kinases that phosphorylate ESCRT‑0 components, accelerating ubiquitination‑dependent cargo sequestration. This creates a positive feedback loop: higher BKCa → heightened calcium signaling → more efficient ESCRT sorting → greater therapeutic payload per vesicle.

Testable Predictions

1. Exosomes engineered to overexpress BKCa (via VSVG‑anchored BKCa fusion) will show a ≥2‑fold increase in loaded siRNA compared with wild‑type exosomes when normalized to particle count.
2. Recipient cells treated with high‑BKCa exosomes will exhibit a transient rise in cytosolic calcium (measured by Fluo‑4 AM) that correlates with increased phosphorylation of ALIX (detected by western blot).
3. Pharmacological blockade of BKCa with paxilline will abolish the calcium spike and reduce cargo loading to baseline levels, confirming causality.
4. In a murine tumor model, high‑BKCa exosomes delivering CRISPR‑Cas9 plasmids will achieve ≥30 % greater gene editing efficiency than standard exosomes, as measured by indel frequency in tumor biopsies.

Experimental Design

• Exosome production: Transfect HEK293T cells with plasmids encoding VSVG‑BKCa and a fluorescent reporter (CD63‑GFP). Isolate exosomes by differential ultracentrifugation and quantify BKCa density using quantitative immunoblotting calibrated to recombinant BKCa standards.
• Cargo loading assay: Electroporate equal amounts of exosomes with a fixed siRNA dose. After removal of free siRNA, extract RNA from exosomes and quantify loaded siRNA by RT‑qPCR. Normalize to exosome particle number (NTA).
• Calcium signaling readout: Incubate recipient HeLa cells with Fluo‑4 AM, add exosomes, and record fluorescence kinetics via live‑cell imaging. Parallel samples receive paxilline (10 µM) or vehicle.
• Downstream sorting assessment: Lyse cells at peak calcium flux, immunoprecipitate ALIX, and probe for phospho‑specific epitopes.
• In vivo efficacy: Inject BKCa‑high or control exosomes bearing CRISPR‑Cas9 plasmid into xenograft tumors. Harvest tumors after 72 h, perform T7E1 assay and next‑generation sequencing to quantify editing.

Falsifiability

If BKCa overexpression fails to augment siRNA loading, does not trigger measurable calcium transients, or fails to improve gene editing outcomes relative to controls, the hypothesis will be refuted. Conversely, consistent positive results across these independent readouts would support the proposed mechanistic link between exosomal ion channel composition, calcium‑mediated sorting machinery, and therapeutic cargo efficiency.